Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 9/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091659 | 0.93 | MPL (0.58) | MPLKDM4EALDH1A1PKMKIT | |
| SCHEMBL1102222 | 0.85 | MPL (0.49) | MPLPKMKITBRD4NR3C1 | |
| SCHEMBL1091673 | 0.85 | MPL (0.54) | MPLKITTDP2BRD4 | |
| SCHEMBL1102199 | 0.82 | MPL (0.56) | MPLKITTDP2NR3C1PGR | |
| SCHEMBL1102218 | 0.82 | MPL (0.51) | MPLALDH1A1TDP2BRD4 | |
| SCHEMBL1102196 | 0.81 | MPL (0.77) | MPL | |
| SCHEMBL1091924 | 0.80 | MPL (1.00) | MPL | |
| SCHEMBL1102276 | 0.80 | MPL (1.00) | MPLAR | |
| SCHEMBL27727188 | 0.78 | MPL (0.64) | MPL | |
| SCHEMBL1102198 | 0.77 | MPL (0.60) | MPLBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8153671-B2 | Heterotetracyclic compounds as TPO mimetics | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| EP-1910338-B1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2010-08-25 | — | — | EP | disclosed |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2009-03-19 | — | — | US | disclosed |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2009-03-19 | — | — | US | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | MPL, TPO, THPO | MPL 1/4885KDM4E 4685/4885ALDH1A1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.